Puma Biotechnology Inc. (PBYI)
NASDAQ: PBYI
· Real-Time Price · USD
3.20
0.12 (3.90%)
At close: May 02, 2025, 3:59 PM
3.21
0.31%
After-hours: May 02, 2025, 04:05 PM EDT
3.90% (1D)
| Bid | 3.16 |
| Market Cap | 158.75M |
| Revenue (ttm) | 230.47M |
| Net Income (ttm) | 30.28M |
| EPS (ttm) | 0.62 |
| PE Ratio (ttm) | 5.16 |
| Forward PE | 9.92 |
| Analyst | Buy |
| Ask | 3.3 |
| Volume | 293,065 |
| Avg. Volume (20D) | 367,288 |
| Open | 3.12 |
| Previous Close | 3.08 |
| Day's Range | 3.07 - 3.25 |
| 52-Week Range | 2.23 - 5.26 |
| Beta | 1.33 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 24, 2012
Employees 172
Stock Exchange NASDAQ
Ticker Symbol PBYI
Analyst Forecast
According to 1 analyst ratings, the average rating for PBYI stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 118.75% from the latest price.
Stock ForecastsNext Earnings Release
Puma Biotechnology Inc. is scheduled to release its earnings on May 8, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+19.73%
Puma Biotechnology shares are trading higher after...
Unlock content with
Pro Subscription
